Egyptian Journal of Obesity, Diabetes and Endocrinology

ORIGINAL ARTICLE
Year
: 2017  |  Volume : 3  |  Issue : 2  |  Page : 39--45

The role of genetic polymorphism of β3-adrenergic receptor in the susceptibility to diabetes and its related disorders: a case–control study on Egyptian population


Neveen S.E.D Hemimi1, Mona M Abdelsalam2, Lamis M Tawfik3, Marwa M Khalil4,  
1 Department of Biochemistry, Endocrine and Metabolism Unit, Ain Shams University, Cairo, Egypt
2 Department of Internal Medicine, Endocrine and Metabolism Unit, Ain Shams University, Cairo, Egypt
3 Department of Clinical Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
4 Department of Community Medicine, Zagazig University, Zagazig, Egypt

Correspondence Address:
Mona M Abdelsalam
Assistant Professor Endocrinology and Metabolism, Department of Internal Medicine, Endocrinology and Metabolism Unit, Faculty of Medicine, Ain Shams University, Abbassia Square, Cairo 11381
Egypt

Abstract

Background The β3-adrenergic receptor (β3-AR) is mainly expressed in adipose tissue and plays an important role in lipid metabolism and metabolic rate by mediating lipolysis and thermogenesis. It has been suggested that the Trp64Arg (T→C) polymorphism in the β3-AR gene affects fat accumulation and/or impairment of lipid and carbohydrate metabolism. Objective The aim of this study was to investigate whether common polymorphism (Trp64Arg) of β3-AR gene has a role in the apparent susceptibility to type 2 diabetes mellitus (DM) and its related disorders in the Egyptian population. Patients and methods One hundred and thirty five healthy controls and 123 individuals with type 2 DM were enrolled in the study. The β3-AR Trp64Arg polymorphism was identified using restriction fragment length polymorphism PCR of peripheral blood DNA samples. Analysis of data was performed using SPSS program 11. Results Allele frequency for C was 23.2% in the diabetic group compared with 12.2% in the control group. The carriers of XC genotype (TC and CC) were at high risk of developing type 2 DM (odds ratio=2.8; 95% confidence interval=1.6–4.9) when compared with the carrier of TT genotype. Furthermore, they were at much higher risk of developing its related disorders such as central obesity, dyslipidemia, and hypertension (odds ratio=2.8; 1.8, 1.5, 2.2, and 2.7 for BMI, waist–hip ratio, triglycerides, high-density lipoprotein, and hypertension, respectively). Conclusion The prevalence of Arg64 allele of the Trp64Arg polymorphism in the β3-AR gene is a risk factor for type 2 DM and its related disorders in the Egyptian population.



How to cite this article:
Hemimi NS, Abdelsalam MM, Tawfik LM, Khalil MM. The role of genetic polymorphism of β3-adrenergic receptor in the susceptibility to diabetes and its related disorders: a case–control study on Egyptian population.Egypt J Obes Diabetes Endocrinol 2017;3:39-45


How to cite this URL:
Hemimi NS, Abdelsalam MM, Tawfik LM, Khalil MM. The role of genetic polymorphism of β3-adrenergic receptor in the susceptibility to diabetes and its related disorders: a case–control study on Egyptian population. Egypt J Obes Diabetes Endocrinol [serial online] 2017 [cited 2018 Feb 24 ];3:39-45
Available from: http://www.ejode.eg.net/text.asp?2017/3/2/39/216792


Full Text



 Introduction



In a region such as Egypt, economic development has led to lifestyle alterations characterized by increases in energy and fat intake and reduction in physical activity. These changes have been associated with a dramatic increase in the prevalence of diabetes and related disorders. Obesity, in particular visceral obesity, appears to be an important link between these disorders [1],[2],[3],[4].

The β3-adrenergic receptor (β3-AR) gene maps to the short arm of chromosome 8; it codes for β3-ARs, which is characterized by the presence of seven hydrophobic regions, corresponding presumably to seven transmembrane domains [5],[6]. It has an extracellular glycated N-terminal domain and intracellular C-terminal domain. The extracellular domain of β3-AR binds the endogenous catecholamines, transfers the signals to the interior of the cells through the stimulatory guanine nucleotide-binding protein (Gs), and regulates basal metabolic rate [5],[7]. Evidence that β3-AR is expressed in visceral fat makes it a prime candidate for regulation of lipolysis in white adipose tissue and insulin sensitivity in humans [5],[8],[9]. This receptor, by stimulating the uncoupling protein-1, alters respiration coupling and dissipates oxidation-derived energy as heat in brown adipose tissue [5],[9],[10]. In rodent, an important mechanism for maintaining constant body weight involves catecholamine-stimulated thermogenesis in brown adipose tissue and skeletal muscle [5],[11]. Furthermore, the treatment of mice with a selective β3-AR agonist led to increased lipolysis and increased insulin levels [5],[12].

In humans, visceral obesity is associated with the enhanced sensitivity of visceral fat to catecholamine-induced lipolysis and delivery of free fatty acid into the portal circulation [5],[13], with subsequent synthesis and release of very low-density lipoprotein from the liver [5],[14].

A common polymorphism in the first intracellular loop has been found in the human β3-AR gene that involves the change in tryptophan (Trp) (TGG) at position 64 to Arg (CGG). Several studies reported an association between the C allele and a marked decrease in β3-AR function [15],[16]. Hence, polymorphism has been associated with obesity through its effect on the energy expenditure of fat tissue [17],[18],[19],[20],[21],[22]. Genetic polymorphism of the β3-AR gene has been proposed as a potential modifying factor in the etiology of type 2 diabetes mellitus (DM) [5],[18],[23],[24], its early onset [5],[18],[20],[23],[24], and the development of features of the insulin resistance syndrome [5],[18],[23],[25].

 Aim



The aim of this study was to investigate whether common polymorphism (Trp64Arg) of β3-AR gene has a role in the apparent susceptibility to type 2 DM and its related disorders in the Egyptian population.

 Patients and methods



Patients

The control group (group I) consisted of 135 healthy individuals (65 male and 70 female) with a mean age of 48.3±8.2 years. The case group (group II) consisted of 123 individuals with type 2 diabetes (61 male and 62 female) with a mean age of 47.5±7.4 years. The study was conducted in the Internal Medicine Department in Ain Shams University Hospitals. All participants signed an informed consent form to participate in the study. Approval was obtained from Ain Shams University, Faculty of Medicine, Research Ethics Committee (FWA00017858).

People with type 2 DM were subjected to full history taking, thorough physical examination, and laboratory tests. Weight, height, and waist and hip circumferences were measured. BMI and waist–hip ratio (WHR) were calculated. Hypertension was defined as blood pressure more than or equal to 140/90 mmHg or current use of antihypertensive medication.

Anthropometric measurements

Individuals with BMI at least 25 kg/m2 were considered positive for overweight/obesity as defined by WHO; those with waist circumference (WC) more than 80 cm for women and more than 94 cm for men or with WHR more than 0.85 for women and more than 1 for men were considered positive for abdominal obesity [26].

Laboratory tests

Lipid profile [total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol, and triglycerides (TG)] was evaluated using routine enzymatic tests (Diasys Kits; DiaSys Diagnostic Systems GmbH, Holzheim, Germany) [27],[28].

DNA extraction

DNA was extracted from white blood cells using a salting-out method [29]. Red blood cell lysis was performed using red cell lysis buffer (20 mmol/l Tris-HCl, pH 7.6) followed by centrifugation. Nuclei lysis was carried out using cell lysis buffer [10 mmol/l Tris-HCl, pH 8.0; 1 mmol/l EDTA, pH 8.0; 0.1% (w/v) SDS] and proteinase K (20 mg/ml) followed by centrifugation. Protein was precipitated using protein precipitation solution (60 ml of 5 mol/l potassium acetate, 11.5 ml of glacial acetic acid, and 28.5 ml of water) followed by centrifugation. Finally, DNA was precipitated using isopropanol and then ethanol 70% followed by centrifugation after each. Pellet of DNA was dried in air and rehydrated in TE buffer (pH 7.6) and stored in −20°C. The DNA purity and concentration were determined by means of spectrophotometer measurement of absorbance at 260 and 280 nm.

Polymorphism detection

Gene was amplified using PCR on 96-well Amp PCR System 9700 Thermocycler (Applied Biosystems, Foster City, California, USA). Primer sequences, PCR conditions, and restriction enzyme digestion were as given below. Oligonucleotides were synthesized using the following primers (Promega Corporation, Madison, WI, USA): the forward primer was 5′-CGCCCAATACCGCCAACAC-3′ and reverse primer was 5′-CCACCAGGAGTCCCATCACC-3′. PCR was carried out in a 50-µl reaction volume containing 100 ng of genomic DNA, 0.4 mmol/l of each primer, 0.2 mmol/l dNTPs, 2 mmol/l MgCl2 in 10% PCR buffer, and 1 U of DNA polymerase (Promega). PCR involved an initial 5-min denaturation at 94°C, 35 cycles of denaturing at 94°C for 30 s, annealing at 61°C for 30 s, and extension at 72°C for 30 s, with a final extension at 72°C for 10 min. Aliquots of 5 µl of the PCR products were digested with 5 U of BstOI (Promega) at 60°C for 2 h. Restriction fragment length polymorphism products were analyzed on 3% agarose gel and stained with ethidium bromide [29]. The TT genotype gave five bands (99, 62, 30, 12, and7 bp), TC gave six bands (161, 99, 62, 30, 12, and 7 bp), and CC gave four bands (161, 30, 12, and 7 bp). The 30, 12, and 7 bp were very small to be resolved on the gel ([Figure 1]).{Figure 1}

Statistical analysis

Genotype and allele frequency were calculated by allele counting as described by Emery [30]. Genotype distribution was investigated in relation to Hardy–Weinberg equilibrium. Three allele groups were considered for β3-AR polymorphism (TT, TC, and CC). The TC and CC were combined together in one group, XC genotype. Statistical analysis was performed with SPSS software, version 11 (SPSS Inc., Chicago, Illinois, USA). Difference in genotype prevalence and association between the case and the control group was assessed using the χ2-test, correlation coefficient, odds ratio (OR), and 95% confidence interval (CI) to describe the strength of association. Mean serum levels for lipids and lipid fractions were compared between different allele groups using Student’s t-test and the Mann–Whitney U-test for nonparametric data. P value less than 0.05 was considered significant.

 Results



The frequency of the T and C alleles in our pooled sample was analyzed; it was 82.6 and 17.4%, respectively. The frequency of genotypes TT, TC, and CC was 69.8, 25.6, and 4.7%, respectively ([Table 1]). The genotypes were found to be within Hardy–Weinberg equilibrium.{Table 1}

The frequencies of different genotypes among the studied groups are shown in [Table 2]. Individuals with XC genotype were at much higher risk of developing DM. OR was 2.8 (OR=2.8, 95% CI=1.6–4.9) when compared with the TT genotype.{Table 2}

Diabetes-related traits, including obesity and dyslipidemia, were measured ([Table 3]). Participants with XC genotype had higher mean BMI (27.97±3.9 vs. 25.7±4.8, P<0.001) and high mean WC (99.5±10.5 vs. 94.9±13.8, P<0.001) when compared with carriers of TT genotype. Similarly, there was a tendency of XC genotype to be associated with a significantly high mean serum level of TG (P<0.01) and a low mean level of HDL (P<0.01) when compared with TT individuals.{Table 3}

All metabolic disorders associated with DM were analyzed and assessed using χ2-test and OR ([Table 4] and [Table 5]). It was clear that individuals with XC were at high risk of developing obesity as measured using BMI, WC, and WHR. Moreover, they were at risk of developing dyslipidemia. The risk for hypertension was estimated to be 2.7. The TT genotype was used as a reference in the previous comparisons.{Table 4}{Table 5}

 Discussion



Sympathetic stimulation of the adipocytes acts in part upon the β3-AR, both in mediating the lipolysis activation at subcutaneous and visceral sites [18] and in the utilizations of intracellular fatty acids in the uncoupled respiration of the thermogenic mitochondria that depends on the uncoupling proteins [31].

To evaluate the biochemical consequences of the Trp64Arg substitution, this change was introduced in the β3-AR gene using site-directed mutagenesis, and it was studied in transfected cells. No change was observed in the binding or adenylyl cyclase activation properties of the Arg64 of β3-AR expressed in CHO or HEK293 cells [32],[33]. However, the absolute amounts of accumulated cyclic AMP were lower in the cells transfected with the polymorphic β3-AR than in the wild type receptors [32]. This may result in lower activation of hormone-sensitive lipase and hence reduce lipolysis [34]. It was found that the Arg64 form deteriorates lipolysis induced by β3-AR agonist in human omental adipocytes [35]. It has been suggested that impaired lipolysis could promote insulin resistance and hyperinsulinism, presumably through enlargement of visceral adipose cells [13].

The overall Arg64 allelic frequency in our pooled sample was 17.4%. Worldwide screening studies have revealed that Arg64 form is actually present in all populations of the world, except for the people of the Pacific island of Nauru [34]. In Pima Indians, the allelic frequency of the variant exceeds 30% [23], and it reaches 19–20% in Japanese [19],[24],[25],[36],[37],[38],[39],[40]. In majority of other populations, the allele frequency is 4.9–13% [18],[20],[23],[41],[42],[43].

In the present study, carriers of Arg64 allele were at a significantly three-fold increased risk of developing type 2 DM compared with carrier of Trp64 allele (OR=2.8, 95% CI=1.6–4.9). The relative contribution of the β3-AR polymorphism to the etiology of type 2 DM is still a matter of debate. Knowler [44] reported that C allele was a risk factor for DM (OR=1.71, 95% CI=1.01–2.89). In meta-analysis, the association was significant [24],[45], leading to the view of a modest, but nevertheless important contribution of the Trp64Arg β3-AR genotype to the polygenic disorders of insulin resistance and type 2 DM [24]. However, in some other studies the association of the β3-AR genotype with the prevalence of type 2 DM failed to reach statistical significance [18],[46],[47]. Moreover, a consistent association with younger age at onset of diabetes (mean difference in age at onset −1.9 years, 95% CI=−2.8 to −1.0) has been reported in several studies [18],[23],[24],[25]. It is likely that Arg64-associated phenotypic alteration might play a role as a promotive factor in an individual genetically predisposed to type 2 DM, resulting in acceleration of the development of DM [45]. In our study Arg64 polymorphism was associated with early onset of DM, although not significant. However, individuals with type 2 DM are often asymptomatic initially and the age of diagnosis may not accurately reflect the age of onset of the diabetes.

The role of polymorphic β3-AR in the pathogenesis of insulin resistance in muscle can be explained by the following: increased deposits of abdominal fat could provide more free fatty acids for the synthesis of very-low-density lipoprotein in the liver, which could result in changes in the fatty acid composition of skeletal muscle membranes [14] or higher concentration of TG in muscle. In rats, the accumulation of TG in muscle is related to the impaired action of insulin [55]. Visceral obesity is also associated with decreased uptake of free fatty acids by muscle and with insulin resistance in skeletal muscle, in particular impaired synthesis of insulin-stimulated glycogen [56]. Insulin resistance is a major predictor of type 2 DM [57].

In the present study, all phenotypic characteristics of insulin resistance were analyzed. Analysis revealed that carriers of the XC genotype were at a relatively higher risk of developing both central and abdominal obesity manifested by the significant increase in their mean BMI and WC when compared with carriers of TT genotype (OR=2.8, 95% CI=1.6–4.8, mean BMI=27.97±3.9 vs. 25.7±4.8, P<0.001, and OR=1.4, 95% CI=0.8–2.5, mean WC=99.5±10.5 vs. 94.9±13.8, P<0.001) for BMI and WC, respectively. Moreover, the relation between the BMI and the different genotypes was dosage related; the mean level of BMI among carriers of different genotypes was 25.7±4.8, 27.8±3.6, and 28.8±5.9 for TT, TC, and CC genotypes, respectively. On analysis of variance the results were significant (P<0.001). Similar results were obtained by Thomas and colleagues, in which the mean BMI was 28.8, 27.9, and 26.6 kg/m2 in CC, CT, and TT, respectively, with a significant increase (P=0.001) using analysis of variance [57]. These markers consistently and significantly increased with increasing proportions of the Arg allele. Clement reported that carriers of Arg 64 allele were not only at risk of weight gain but also they resist weight loss [20],[37].

In a meta-analysis study by Fujisawa and colleagues, using data from more than 9000 individuals, a significant association of the Trp64Arg polymorphism with BMI was found (mean difference in BMI=0.3, 95% CI=0.13–0.47 kg/m2) [45]. In addition, the association among the diverse population groups exhibited a relatively similar strength despite the different genetic (including distribution of β3-AR genotypes) and environmental backgrounds. Therefore, the β3-AR locus has been shown for the first time to be a genetic factor associated with body weight in a universal manner [45]. Moreover, Tchernof et al. [58] confirmed the previous finding. However, in a study on the association of Arg64 with BMI and body weight, it was found to be significant in men not in women. Body weight was 11.8 kg more in homozygous CC (P<0.001) and BMI was 3.7 kg/m2 greater in CC (P=0.001) than in homozygous TT [16]. Some studies failed to replicate the association of Arg64 with obesity [42],[59],[60],[61].

In the present study, the Arg allele was associated with atherogenic lipid profile manifested by significantly high mean level of TG and a low mean level of HDL-C (P<0.01). Carrier of XC genotype was at a significantly higher risk of having low HDL-C (OR=2.2, 95% CI=1.2–3.8) when compared with carriers of TT genotype. In another study, Arg64 allele was associated with a significant decrease in HDL and a significant increase in TG, whereas the increase in TC and low-density lipoprotein was nonsignificant [62],[63]. However, some studies failed to replicate our results [16],[64].

In general, as understanding the genetic and environmental parameters that contribute to diabetes may lead to earlier identification of individuals at risk and to more effective interventions to prevent the development or progression of the disease and its complications. It is recommended to focus more studies on the genetic susceptibility of the different ethnic groups to diabetes and its complications.

 Conclusion



The prevalence of Arg 64 allele of the Trp64Arg polymorphism in the β3-AR gene is a risk factor for type 2 DM and its related disorders in the Egyptian population.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1Despres JP, Allard C, Tremblay A, Talbot J, Bouchard C. Evidence for a regional component of body fatness in the association with serum lipids in men and women. Metabolism 1985; 34:967–973.
2Després JP. Health consequences of visceral obesity. Ann Med 2001; 33:534–541.
3Chan JCN, Cheung JCK, Lau EMC, Woo J, Chan AYW, Cockram CS. The metabolic syndrome I Homf Kong Chinese. The interrelationships among its components analyzed by structural equation modeling. Diabetes Care 1996; 19:935–959.
4Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27:1047–1053.
5Vieira-Filho JPB, Reis AF, Kasamatsu TS, Tavares EF, Franco LJ, Matioli SR, Moisés RS. Influence of the polymorphisms Tpr64Arg in the β3-adrenergic receptor gene and Pro12Ala in the PPARγ2 gene on metabolic syndrome-related phenotypes in an indigenous population of the Brazilian Amazon. Diabetes Care 2004; 27:621–622.
6Strosberg AD. Association of beta 3-adrenoceptor polymorphism with obesity and diabetes: current status. Trends Pharmacol Sci 1997; 18:449–454.
7Meirenhaeghe A, Luan J, Selberg-Franks P. The effect o the Gly16Arg polymorphism of the β2-adrenergic receptor gene on plasma free fatty acids levels is modulated by physicalactivity. J Clin Endocrinol Meta 2001; 86:5881–5887.
8Hoffstedt J, Shimizu M, Sjostedt S, Lonnqvist F. Determination of β3-adrenergic receptor mediated lipolysis in human fat cells. Obes Res 1995; 3:447–457.
9Hod M, Rabinerson D, Kaplan B. Preinatal complications following gestational diabetes mellitus how sweet is ill? Acta Obstet Gynecol Scand 1996; 75:809–815.
10Clement K, Ruiz J, Cassard-Doulcier AM. Additive effect od A-G (3826) variant of the uncoupling protein gene and the Trp64Arg mutation of the β3-adrenergic receptor gene on weight gain in morbid obesity. Int J Obes Relat Metab Disord 1996; 20:1062–1066.
11Cnattingius S, Bergstrom R, Lipworth L, Kramer MS. Prepregnancy weight and the risk of adverse pregnancy outcomes. N Engl J Med 1998; 338:147–152.
12Grujic D, Susulic VS, Harper ME. B3 adrenergic-receptors on white and brown adipocytes mediate B3 selective agonist induced effects on energy expenditure, insulin secretion, food intake. J Biol Chem 1997; 272:17686–17693.
13Lonnqvist F, Thorne A, Nilsell K, Hoffstedt J, Arner P. A pathogenetic role of visceral fat β3 adrenoreceptos in obesity. J Clin Invest 1995; 95:1109–1116.
14Bork M, Storlien LH, Pan DA, Jenkins AB, Chisholm DJ, Campbell LV. The relationship between insulin sensitivity and the fatty acid compostion of skeletal muscle phospholipids. N Engl J Med 1993; 328:238–244.
15Hoffstedt J, Poirier O, Thorne A, Lonnqvist F, Herrmann SM, Cambien F, Arner P. Polymorphism of the human beta3-adrenoceptor gene forms a well-conserved haplotype that is associated with moderate obesity and altered receptor function. Diabetes 1999; 48:203–205.
16Hao K, ShaoJie P, HouXun X, YunXian Y. β3 adrenergic receptor polymorphism and obesity phenotypes in hypertensive patients. Obes Res 2004; 12:125–130.
17Emorine L, Blin N, Strosberg AD. The human Emorine L, Blin N, Strosberg AD. The human β3-adrenergic receptor: the search for a physiological function. Trends Pharmacol Sci 1994; 15:3–7.
18Widen E, Lehto M, Kanninen T, Walston J, Shuldiner AR, Groop LC. Association of a polymorphism in the beta 3-adrenergic-receptor gene with features of the insulin resistance syndrome in Finns. New Engl J Med 1995; 333:348–351.
19Kadowaki H, Yasuda K, Iwamoto K, Otabe S, Shimokawa K, Silver K et al. A mutation in the beta 3-adrenergic receptor gene is associated with obesity and hyperinsulinemia in Japanese subjects. Biochem Biophys Res Commun 1995; 215:555–560.
20Clement K, Vaisse C, Manning BS, Basdevant A, Guy-Grand B, Ruiz J et al. Genetic variation in the beta 3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity. New Engl J Med 1995; 333:352–354.
21Kim-Motoyama H, Yasuda K, Yamaguchi T, Yamada N, Katakura T, Shuldiner AR et al. A mutation of the beta 3-adrenergic receptor is associated with visceral obesity but decreased serum triglyceride. Diabetologia 1997; 40:469–472.
22McFarlane-Anderson N, Bennett T. The Trp64Arg mutation of the the β3-adrenergic receptor is associated with hyprglycemia and current body mass index in Jamaican women. Metabolism 1998; 47:617–621.
23Walston J, Silver K, Bogardus C, Knowler WC, Celi FS, Austin S et al. Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the beta 3-adrenergic-receptor gene. New Engl J Med 1995; 333:343–347.
24Fujisawa T, Ikegami H, Yamato E, Takekawa K, Nakagawa Y, Hamada Y et al. Association of Trp64Arg mutation of the beta3-adrenergic-receptor with NIDDM and body weight gain. Diabetologia 1996; 39:349–352.
25Sakane N, Yoshida T, Umekawa T, Kogure A, Takakura Y, Kondo M. Effects of Trp64Arg mutation in the beta 3-adrenergic receptor gene on weight loss, body fat distribution, glycemic control, and insulin resistance in obese type 2 diabetic patients. Diabetes Care 1997; 20:1887–1890.
26World Health Organization. Preventing and managing the Global Epidemic. Report of a WHO Consultation. WHO Technical Report Series 894. 2000. Available at: http://www.who.int/nutrition/publications/obesity/WHO_TRS_894/en/. Languages: English (reprinted 2004), French (2003).
27Friedwald WT, Levy RI, Fredrickdson DS. Estimation of the low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifugation. Clin Chem 1997; 18:499–502.
28Rifal N, Bachnorik PS, Albers JJ. Lipids, lipoproteins and apolipoproteins. In: Burtis CA, Ashwood ER, editors. Tietz text book of clinical chemistry. 3rd ed. Philadelphia: WB Saunders Company; pp. 809–861.
29Josef S, David WR, Nina I, Kaaren AJ. Molecular cloning: rapid isolation of mammalian DNA. New York: Cold Spring Harbour Laboratory Press; 2002. pp. 628–630.
30Emery AEH. Methodology in medical genetics – an introduction to statistical methods. Edinburgh: Longman Group Ltd; 1986.
31Palou A, Pico C, Bonet ML, Oliver P. Molecules in focus: uncoupling protein. Int J Biochem Cell Biol 1998; 30:7–11.
32Pietri-Rouxel F, Manning BSJ, Gros J, Stosberg AD. The biochemical effect of the naturally occurring Trp64Arg mutation on human B3 adrenoreceptor activity. Euro J Biochem 1997; 1174–1179
33Candelore MR, Deng L, Tota LM, Kelly LJ. Pharmacological characterization of a recently descrived human B3 adrenergic receptor mutant. Endocrinology 1996; 137:2638–2641.
34Yoshida T, Sakane N. Association between B3- adrenoreceptor polymorphism with obesity and diabetes in Japan. Intern Med 1999; 38:207–209.
35Umekawa T, Yoshida T, Sakane N, Kogure A. Trp64Arg mutation of B3 adrenoreceptor agonist in human omental adipocytes. Diabetes 1999; 48:117–120.
36Yoshida T, Sakane N, Umekawa T, Sakai M, Takahashi T, Kondo M. Mutation of 3-adrenergic-receptor gene and response to treatment of obesity. Lancet 1995; 346:1433–1434.
37Yoshioka K, Yoshida T, Sakane N, Umekawa T, Takahashi T, Sakai Y, Kondo M. Association of Trp64Arg mutation of the beta 3-adrenergic receptor gene with NIDDM, current and maximal body mass index. Diabetologia 1996; 39:1410–1414.
38Sakane N, Yoshida T, Umekawa T, Kondo M, Sakai Y, Takahashi T. Beta 3-adrenergic-receptor polymorphism: a genetic marker for visceral fat obesity and insulin resistance syndrome. Diabetologia 1997; 40:200–204.
39Sakane N, Yoshida T, Yoshioka K, Nakamura N, Umekawa N, Kogure N. β3-adrenoreceptor gene polymorphim: a newly identified risk factor for proliferative retinopathy in NIDDM patients. Diabetes 1997; 46:1633–1636.
40Sakane N, Yoshida T, Yoshioka K, Godson C, Martin F. 1T9r9p76. 4Arg mutation of b3-adrenoceptor gene is associated with diabetic nephropathy in type II diabetes mellitus. Diabetologia 1998; 41:1533–1534.
41Urhammer SA, Clausen JO, Hansen T, Pedersen O. Insulin sensitivity and body weight changes in young white carriers of the codon 64 amino acid polymorphism of the beta 3-adrenergic receptor gene. Diabetes 1996; 45:1115–1120.
42Li LS, Lönnqvist F, Luthman H, Arner P. Phenotypic characterization of the Trp64Arg polymorphism in the beta3-adrenergic receptor gene in normal weight and obese subjects. Diabetologia 1996; 39:857–860.
43Kurabayashi T, Carey DG, Morrison NA. The beta 3-adrenergic receptor gene Trp64Arg mutation is overrepresented in obese women. Effects on weight, BMI, abdominal fat, blood pressure, and reproductive history in an elderly Australian population. Diabetes 1996; 45:1358–1363.
44Knowler WC. Association of Trp64Arg mutation o the b3-adrenergic receptor gene with NIDDM. Diabetologia 1996; 39:1410–1411.
45Fujisawa T, Ikegami H, Kawaguchi Y. Meta-analysis of the association of Trp64 Arg polymorphism of the β3-adrenergic receptor gene with body mass index. J Clin Endocrinol Metab 1998; 7:2441–2444.
46Zhang Y, Wat N, Stratton IM. UKPDS 19: heterogeneity in NIDDM: separate contributions of IRS-1 and B3-adrenergic-receptor mutations to insulin resistance and obesity respectively with no evidence for glycogen synthase gene mutations. Diabtologia 1996; 39:1505–1511.
47Rissanen J, Kuopusjarvi J, Pihlajamaki J, Sipiläinen R, Heikkinen S, Vanhala M et al. The Trp64Arg polymorphism of the beta3-adrenergic receptor gene. Lack of association with NIDDM and features of insulin resistance syndrome. Diabetes Care 1997; 20:1319–1323.
48Silver K, Mitchell BD, Walston J, Sorkin JD, Stern MP, Roth J, Shuldiner AR. TRP64ARG beta 3-adrenergic receptor and obesity in Mexican Americans. Hum Genet 1997; 101:306–311.
49Awata T, Katayama S. Genetic variation in the β3-adrenergic-receptor in Japanese NIDDM patients. Diabetes Care 1996; 19:271–272.
50Sakane N, Yoshida T, Yoshioka K, Umekawa T, Takakura Y, Kogure A, Kondo M. Genetic variation in the beta 3-adrenergic-receptor in Japanese NIDDM patients. Diabetes Care 1996; 19:1034–1035.
51Elbein SC, Hoffman M, Barrett K, Wegner K, Miles C, Bachman K et al. Role of the beta 3-adrenergic receptor locus in obesity and non-insulin-dependent diabetes among members of Caucasian families with a diabetic sibling pair. J Clin Endocrinol Metab 1996; 81:4422–4427.
52Oksanen L, Mastajoki P, Kaprio J, Kainulainen K, Jänne O, Peltonen L, Kontula K. Polymorphism of the beta 3-adrenergic receptor gene in morbid obesity. Int J Obes Relat Metab Disord 20:1055–1061.
53Ueda K, Tanizawa Y, Oota Y, Inoue H, Kizuki N, Inoue H et al. Prevalence of the Trp64Arg missense mutation of the β3-adrenergic receptor gene in Japanese subjects. Metabolism 1997; 46:199–202.
54Jeyasingam CL, Bryson JM, Caterson ID, Yue DK, Donnelly R. Expression of the of β3-adrenoceptor gene polymorphism (Trp64Arg) in obese diabetic and non-diabetic subjects. Clin Exp Pharmcol Physiol 1997; 24:733–735.
55Storlien LH, Jenkins AB, Chisholm DJ, Pascoe WS, Khouri S, Kraegen EW. Influence of dietary fat compostion on development of insulin resistance in rats: relationship to muscle triglyceride and w-3 fatty acids in muscle phospholipid. Diabetes 1991; 40:280–289.
56Colberg SR, Simoneau J-A., Thaete FL, Kelley DE. Skeletal muscle utilization of free fatty acids in women with visceral obesity. J Clin Ivest 1995; 95:1846–1853.
57Martin BC, Warram JH, Krolewski AS, Bergman RN, Soeldner JS, Khan CR. Role of glucose and insulin resistance in development of type 2 diabetes mellitus:results of a 25-year follow-up study. Lancet 1992; 340:925–929.
58Tchernof A, Starling RD, Silver K, Matthews DE, Poehlman ET. Obesity related phenotypes and β3-adrenergic receptor gene variant in postmenopausal women. Diabetes 1999; 48:1425–1428.
59Chagnon YC, Perusse L, Bouchard C. Familial aggregation of obesity, candidate genes and quantitative trait loci. Curr Opin Lipidol 1997; 8:205–211.
60Moriatry M, Wing RR, Kuller LH, Ferrell RE. Trp64Arg substitution in the β3-adrenergic receptor does not relate to body weight in healthy, premenopousal women. Int J Obes Relat Metab Disord 1997; 21:826–829.
61Nagase T, Aoki A, Yamamoto M, Yasuda H, Kado S, Nishikawa M et al. Lack of association between the Trp64Arg mutation in the of β3-adrenergic receptor gene and obesity in Japanese men: a longitudinal analysis. J Clin Endocrnol Metab 1997; 82:1284–1287.
62Ghosh S, Langefeld CD, Ally D, Watanabe DRMK, Hauser ER. The W64R variant of the b3-adrenergic receptor is not associated with Type II diabetes or obesity in a large Finnish sample. Diabetologia. 1999; 42:238–244.
63Yamauchi T, Kuno T, Takada H. The impact of Trp64Arg mutation in the β3-adrenergic receptor gene on hemodialysis patients. Nephrol Dial transplant 2001; 16:641–642.
64Luis DA, Aller R, Izaola O, Gonzalez M, Conde R. Relation of Trp64Arg polymorphism of β3-adrenergic-receptor gene to adipocytokines and fat distribution in obese patients. Ann Nutr Metab 2008; 52:267–271.